# CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

> **NCT01010061** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 787 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** obinutuzumab
- **DRUG:** rituximab
- **DRUG:** chlorambucil

## Key facts

- **NCT ID:** NCT01010061
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-21
- **Primary completion:** 2012-07-01
- **Final completion:** 2017-08-23
- **Target enrollment:** 787 (ACTUAL)
- **Last updated:** 2018-09-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010061, "CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01010061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*